Multimodal imaging and intravitreal faricimab for polypoidal choroidal vasculopathy associated with a choroidal nevus in genetically confirmed Usher syndrome type 2: a case report Authors: Jiyong Kim, Jaehwan Choi, Kiyoung Kim, Seung-Young Yu Published: 2026 ABSTRACT BackgroundUsher syndrome is an autosomal recessive disorder characterized by retinitis pigmentosa (RP), sensorineural hearing loss, and vestibular dysfunction. Polypoidal choroidal vasculopathy (PCV) is characterized by branching neovascular networks and polypoidal lesions. While typically classified within the pachychoroid spectrum, PCV can also manifest in eyes without choroidal thickening. Conversely, RP is usually associated with choroidal thinning, which may lead to underdiagnosis of PCV. To the best of our knowledge, PCV has not previously been reported in patients with Usher syndrome. Here, we present the first genetically confirmed case of Usher syndrome type 2 complicated by PCV that was successfully managed with intravitreal faricimab.Case presentationA 63-year-old man presented with night blindness. The diagnosis of Usher syndrome type 2 was confirmed based on bilateral RP features, moderate sensorineural hearing loss, and two pathogenic USH2A variants. Six years after the initial diagnosis, the patient developed visual disturbance in the left eye, with the best-corrected visual acuity (BCVA) declining to 20/80. Multimodal imaging, including spectral-domain optical coherence tomography, fluorescein angiography, indocyanine green angiography, and swept-source optical coherence tomography angiography, confirmed the diagnosis of PCV. An amelanotic choroidal nevus was also identified on SD-OCT. After five intravitreal faricimab injections, the BCVA improved to 20/30, with a 75% reduction in pigment epithelial detachment height and complete subretinal fluid resolution without adverse effects.ConclusionsTo our knowledge, this is the first reported case of PCV associated with a choroidal nevus in a patient with genetically confirmed Usher syndrome type 2. PCV should not be excluded in patients with RP despite characteristic choroidal thinning. Intravitreal faricimab was effective and well-tolerated, suggesting its therapeutic potential in such cases. Background Usher syndrome is an autosomal recessive genetic disorder characterized by vision loss caused by retinitis pigmentosa (RP), sensorineural hearing loss, and vestibular dysfunction [1]. This condition is the most common cause of inherited deaf-blindness, with a reported prevalence ranging from 1/6000 to 1/10,000 [2]. Usher syndrome type 2 accounts for more than half of all cases and is characterized by moderate sensorineural hearing loss without vestibular dysfunction, with RP typically developing in the second decade of life [3]. Pathological mutations in USH2A may be responsible for Usher syndrome type 2 [4]. In patients with Usher syndrome associated with USH2A mutations, the median age of legal blindness based on visual acuity and/or visual field was 52 years [5]. Polypoidal choroidal vasculopathy (PCV) is characterized by branching neovascular networks (BNNs) and polypoidal lesions [6]. A thickened choroid is typically considered a hallmark of pachychoroid diseases, including PCV [6]. However, PCV can also manifest in eyes without choroidal thickening, such as those with high myopia [7]. In contrast, RP is characterized by a thin choroid [8–11]. This discrepancy in typical choroidal thickness between RP and PCV may lead clinicians to overlook the possibility of PCV in patients already diagnosed with RP. As RP initially causes mid-peripheral visual field defects, whereas PCV affects central vision, the development of PCV in patients with RP can lead to further vision loss. Although rare, the association between RP and PCV has been described in several case reports [12–14]. However, to the best of our knowledge, the development of PCV in patients with Usher syndrome has not been previously reported. We report the first case of PCV in a patient diagnosed with Usher syndrome type 2. Case presentation A 63-year-old man presented with a six-month history of night blindness. At presentation, the best-corrected visual acuity (BCVA) was 20/40 and 20/30 in the right and left eyes, respectively. Slit-lamp examination revealed no significant abnormalities, except for cortical cataracts in both eyes. Fundoscopic examination demonstrated bone spicule pigmentary changes extending from the parafoveal area in both eyes and an epiretinal membrane in the right eye. Fundus autofluorescence (FAF) imaging demonstrated a hyperautofluorescent ring in both eyes, and spectral domain optical coherence tomography (SD-OCT) revealed reduced subfoveal choroidal thickness (SFCT) in both eyes (right: 129 μm, left: 143 μm) [15]. Humphrey visual field testing confirmed that the remaining visual fields were 10 degrees in both eyes (Fig. 1). Moreover, full-field electroretinography revealed flat waves in both eyes. The patient also exhibited sensorineural hearing loss, particularly in the high-frequency range in the left ear and mixed-type hearing loss due to chronic otitis media in the right ear. Vestibular function tests revealed no abnormalities. Considering the patient’s symmetrical RP and moderate sensorineural hearing loss, a clinical diagnosis of Usher syndrome was established. Next-generation sequencing-based panel tests targeting the RP were performed to confirm the diagnosis. This analysis identified two pathogenic variants in the USH2A exome, a truncating variant [NM_206933.4:c.4957 C > T] and a canonical splice site mutation [NM_206933.4:c.9258 + 1G > T], providing strong genetic evidence to support the clinical diagnosis of Usher Syndrome type 2 [16, 17]. Fig. 1Baseline features of the patient. (a, b) Fundus photographs of both eyes display peripheral bony spicule-like pigmentary changes. (c, d) Fundus autofluorescence images of both eyes reveal a hyperautofluorescent ring surrounding the macula. (e, f) Humphrey visual field tests reveal constriction of the visual field within 10° in both eyes. (g, h) Spectral-domain optical coherence tomography of both eyes demonstrates thin subfoveal choroidal thickness (Right: 129 μm, left: 143 μm) Baseline features of the patient. (a, b) Fundus photographs of both eyes display peripheral bony spicule-like pigmentary changes. (c, d) Fundus autofluorescence images of both eyes reveal a hyperautofluorescent ring surrounding the macula. (e, f) Humphrey visual field tests reveal constriction of the visual field within 10° in both eyes. (g, h) Spectral-domain optical coherence tomography of both eyes demonstrates thin subfoveal choroidal thickness (Right: 129 μm, left: 143 μm) The patient was regularly followed up, and the BCVA and visual field remained stable. However, six years after the initial visit, the patient reported additional visual disturbances in the left eye. The BCVA decreased to 20/80, and SD-OCT revealed pigment epithelial detachment (PED) and subretinal fluid (SRF) in the left eye macula, as well as an anteriorly bowed choroidal lesion suggestive of an amelanotic nevus [18]. Fluorescein angiography (FA) and indocyanine green angiography (ICGA) revealed a polypoidal lesion with an associated BNN, confirming the diagnosis of PCV. Swept-source optical coherence tomography angiography (SS-OCTA) was used to visualize the neovascular structures, including the BNN and a polypoidal lesion (Fig. 2). Fig. 2Multimodal imaging of the left eye at the time of polypoidal choroidal vasculopathy diagnosis. (a) Color fundus photographs display an orange-red lesion near the macula. (b) Fluorescein angiography and (c) indocyanine green angiography images demonstrate a hyperfluorescent hot spot corresponding to a polypoidal lesion with an associated branch neovascular network. (d) En face image from swept-source optical coherence tomography angiography visualizes the branch neovascular network with a polypoidal lesion. (e, f) Spectral-domain optical coherence tomography images reveal thin subretinal fluid and a polypoidal lesion; yellow arrows indicate the amelanotic nevus Multimodal imaging of the left eye at the time of polypoidal choroidal vasculopathy diagnosis. (a) Color fundus photographs display an orange-red lesion near the macula. (b) Fluorescein angiography and (c) indocyanine green angiography images demonstrate a hyperfluorescent hot spot corresponding to a polypoidal lesion with an associated branch neovascular network. (d) En face image from swept-source optical coherence tomography angiography visualizes the branch neovascular network with a polypoidal lesion. (e, f) Spectral-domain optical coherence tomography images reveal thin subretinal fluid and a polypoidal lesion; yellow arrows indicate the amelanotic nevus After three monthly loading intravitreal faricimab injections (6.0 mg/0.05 mL; Vabysmo, Roche Pharma AG, Grenzach-Wyhlen, Germany) followed by two additional injections administered using a pro-re-nata (PRN) regimen, the BCVA improved to 20/30, whereas SD-OCT revealed a decrease in PED height and complete SRF resolution (Fig. 3). The patient underwent regular follow-up and showed no evidence of recurrence. Fig. 3Comparison of spectral domain optical coherence tomography (SD-OCT) images before and after intravitreal faricimab treatment. (a) Baseline SD-OCT scan through the fovea shows subretinal fluid (SRF). (b) SD-OCT scan of the same foveal section after five injections shows resolution of SRF. (c) Baseline SD-OCT scan shows a pigment epithelial detachment (PED). (d) SD-OCT scan of the same lesion after five injections shows a significant reduction in the size of the PED Comparison of spectral domain optical coherence tomography (SD-OCT) images before and after intravitreal faricimab treatment. (a) Baseline SD-OCT scan through the fovea shows subretinal fluid (SRF). (b) SD-OCT scan of the same foveal section after five injections shows resolution of SRF. (c) Baseline SD-OCT scan shows a pigment epithelial detachment (PED). (d) SD-OCT scan of the same lesion after five injections shows a significant reduction in the size of the PED Discussion and conclusions PCV has rarely been documented in patients with RP, with only a few cases described in previous literature [12–14]. All previously reported patients were successfully treated without permanent adverse events using various therapeutic regimens, including intravitreal ranibizumab injections combined with photodynamic therapy, intravitreal aflibercept monotherapy, and intravitreal bevacizumab injections, without genetic testing for RP (Table 1) [12–14]. Notably, however, no previous reports have highlighted PCV occurring in a patient diagnosed with Usher syndrome, either clinically or with genetic confirmation [19]. To the best of our knowledge, this is the first reported case of PCV associated with a choroidal nevus in a patient with genetically confirmed Usher syndrome, which was successfully managed using intravitreal faricimab. Throughout the treatment, no adverse effects related to the intravitreal anti-vascular endothelial growth factor (VEGF) injections were observed. The patient’s BCVA remained stable, and structural improvements, as evidenced by SD-OCT, demonstrated a 75% reduction in PED height and complete resolution of the SRF. Furthermore, SS-OCTA revealed partial regression of the BNN. The patient reported stable subjective symptoms, including visual disturbances and visual field preservation. In this case, the PCV is considered primarily due to the underlying choroidal nevus. Previous studies have documented the development of PCV overlying choroidal nevi following chronic mechanical compression of the choriocapillaris by the nevus and subsequent local ischemia [20–24]. The topographic correspondence between the nevus and the PCV lesion in our patient is consistent with this well-established association. Additionally, the reduced choroidal blood flow associated with RP may have further contributed to the susceptibility for neovascularization in this patient [25, 26]. As patients with PCV usually demonstrate a thickened choroid compared to age-matched controls, clinicians may overlook the possibility of PCV in patients with RP due to the contrasting choroidal characteristics [27]. However, as demonstrated in our case and in eyes with high myopia, PCV can manifest in thinned choroidal environments [7]. Therefore, the diagnosis of PCV should not be excluded in patients with RP presenting with subretinal exudation despite the paradoxical difference in choroidal thickness. Clinicians should be vigilant for concurrent choroidal pathologies, such as amelanotic nevi, that may serve as a primary driver of PCV. Since amelanotic nevi can be difficult to identify on color fundus photography, structural evaluation using SD-OCT is essential. To the best of our knowledge, this is the first reported case of PCV in a patient with RP who was treated with intravitreal faricimab. Faricimab has demonstrated significant efficacy in preserving and improving vision in treatment-naïve patients with neovascular age-related macular degeneration, with a 50% regression rate for polypoidal lesions in PCV [28]. Based on these findings, faricimab was selected to optimize central vision preservation in this patient. This case report had several limitations. First, as a single-case study, the safety and efficacy of intravitreal faricimab injections cannot be generalized, and a large case series is required to validate these observations. Second, repeat ICGA was not performed to confirm polyp closure due to the invasive and costly nature of the procedure. Instead, treatment response was monitored using non-invasive SD-OCT and visual acuity assessments. Third, late recurrence or delayed adverse effects may have been missed due to the lack of long-term follow-up. In conclusion, we present the first documented case of PCV associated with a choroidal nevus in a patient with genetically confirmed Usher syndrome type 2. This report highlights the importance of vigilant diagnosis for PCV in patients with RP to facilitate appropriate and timely treatment. Furthermore, our findings suggest that intravitreal faricimab is a safe and effective therapeutic option in patients with Usher syndrome presenting with PCV. Table 1Clinical characteristics and treatment outcomes of previously reported cases of PCV in patients with RPAge/SexBaseline FeaturesOphthalmic TreatmentTreatment OutcomeAuthor63/FBCVA: 20/100Visual field: Concentric constrictionFundus examination: Bilateral retinal findings of RPOCT: Large hemorrhagic PED and polypoidal lesionsFA and ICGA: Multiple polypoidal lesionsThree consecutive intravitreal injections of ranibizumab with a single application of photodynamic therapyNo adverse effectStable BCVA (20/100)No progression of visual field defectRegression of a polypoidal lesionUnchanged PEDIshida et al., 201371/FBCVA: 20/400Visual field: Concentric constrictionFundus examination: Typical RP featuresFAF: Ring hyper-autofluorescence and patchy hypo-autofluorescent areas in the posterior pole and peripheral regionsOCT: SRF, PED, and polypoidal lesionsFA and ICGA: Polypoidal lesionsSix intravitreal aflibercept injectionsNo adverse effectImprovement of BCVA (20/400 ◊ 20/133)No progression of visual field defectAbsence of SRF and PCVTakahashi et al., 202163/FBCVA: 20/125Fundus examination: Features of sector RPFAF: Hypo-autofluorescent areasOCT: SRF, PED, and dilation of outer choroidal vesselsFA and ICGA: Polypoidal lesions with a branch neovascular networkIntravitreal bevacizumab injectionNo adverse effectStable BCVA (20/125)Reduction in SRF and size of PEDAppranraj et al., 2023BCVA, best-corrected visual acuity; RP, retinitis pigmentosa; FA, Fluorescein angiography; ICGA, Indocyanine green angiography; OCT, optical coherence tomography; PED, pigment epithelium detachment; FAF, fundus autofluorescence; SRF, subretinal fluid Table 1Clinical characteristics and treatment outcomes of previously reported cases of PCV in patients with RPAge/SexBaseline FeaturesOphthalmic TreatmentTreatment OutcomeAuthor63/FBCVA: 20/100Visual field: Concentric constrictionFundus examination: Bilateral retinal findings of RPOCT: Large hemorrhagic PED and polypoidal lesionsFA and ICGA: Multiple polypoidal lesionsThree consecutive intravitreal injections of ranibizumab with a single application of photodynamic therapyNo adverse effectStable BCVA (20/100)No progression of visual field defectRegression of a polypoidal lesionUnchanged PEDIshida et al., 201371/FBCVA: 20/400Visual field: Concentric constrictionFundus examination: Typical RP featuresFAF: Ring hyper-autofluorescence and patchy hypo-autofluorescent areas in the posterior pole and peripheral regionsOCT: SRF, PED, and polypoidal lesionsFA and ICGA: Polypoidal lesionsSix intravitreal aflibercept injectionsNo adverse effectImprovement of BCVA (20/400 ◊ 20/133)No progression of visual field defectAbsence of SRF and PCVTakahashi et al., 202163/FBCVA: 20/125Fundus examination: Features of sector RPFAF: Hypo-autofluorescent areasOCT: SRF, PED, and dilation of outer choroidal vesselsFA and ICGA: Polypoidal lesions with a branch neovascular networkIntravitreal bevacizumab injectionNo adverse effectStable BCVA (20/125)Reduction in SRF and size of PEDAppranraj et al., 2023BCVA, best-corrected visual acuity; RP, retinitis pigmentosa; FA, Fluorescein angiography; ICGA, Indocyanine green angiography; OCT, optical coherence tomography; PED, pigment epithelium detachment; FAF, fundus autofluorescence; SRF, subretinal fluid Clinical characteristics and treatment outcomes of previously reported cases of PCV in patients with RP BCVA: 20/100 Visual field: Concentric constriction Fundus examination: Bilateral retinal findings of RP OCT: Large hemorrhagic PED and polypoidal lesions FA and ICGA: Multiple polypoidal lesions No adverse effect Stable BCVA (20/100) No progression of visual field defect Regression of a polypoidal lesion Unchanged PED BCVA: 20/400 Visual field: Concentric constriction Fundus examination: Typical RP features FAF: Ring hyper-autofluorescence and patchy hypo-autofluorescent areas in the posterior pole and peripheral regions OCT: SRF, PED, and polypoidal lesions FA and ICGA: Polypoidal lesions No adverse effect Improvement of BCVA (20/400 ◊ 20/133) No progression of visual field defect Absence of SRF and PCV BCVA: 20/125 Fundus examination: Features of sector RP FAF: Hypo-autofluorescent areas OCT: SRF, PED, and dilation of outer choroidal vessels FA and ICGA: Polypoidal lesions with a branch neovascular network No adverse effect Stable BCVA (20/125) Reduction in SRF and size of PED BCVA, best-corrected visual acuity; RP, retinitis pigmentosa; FA, Fluorescein angiography; ICGA, Indocyanine green angiography; OCT, optical coherence tomography; PED, pigment epithelium detachment; FAF, fundus autofluorescence; SRF, subretinal fluid